Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development

por Yap, Timothy A., Jacobs, Ira, Baumfeld Andre, Elodie, Lee, Lauren J., Beaupre, Darrin, Azoulay, Laurent
Publicado 2022

Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations

por Barry, Elly, Walsh, Jaimie A., Weinrich, Scott L., Beaupre, Darrin, Blasi, Eileen, Arenson, Daniel R., Jacobs, Ira A.
Publicado 2021

Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma

por Wilson, Wyndham H., Phillips, Tycel, Popplewell, Leslie, de Vos, Sven, Chhabra, Saurabh, Kimball, Amy S., Beaupre, Darrin, Huang, Da Wei, Wright, George, Kwei, Kevin, Ping, Jerry, Neuenburg, Jutta K., Staudt, Louis M.
Publicado 2021

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors

por Hong, David S., Rosen, Peter, Lockhart, A. Craig, Fu, Siqing, Janku, Filip, Kurzrock, Razelle, Khan, Rabia, Amore, Benny, Caudillo, Isaac, Deng, Hongjie, Hwang, Yuying C., Loberg, Robert, Ngarmchamnanrith, Gataree, Beaupre, Darrin M., Lee, Peter
Publicado 2015

The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma

por Fowler, Nathan H., Nastoupil, Loretta, De Vos, Sven, Knapp, Mark, Flinn, Ian W., Chen, Robert, Advani, Ranjana H., Bhatia, Sumeet, Martin, Peter, Mena, Raul, Davis, Richard Eric, Neelapu, Sattva S., Eckert, Karl, Ping, Jerry, Co, Melannie, Beaupre, Darrin M., Neuenburg, Jutta K., Palomba, M. Lia
Publicado 2020